CABLIVI 10 mg, powder and solvent for solution for injection 7 bottles of 1 ml
Active ingredients: Caplacizumab
Commercialized according to BDPMDispensing in France: Prescription only
Powder and solvent for solution for injection7 bottles of 1 mlintraveineuse;sous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- CABLIVI 10 mg, poudre et solvant pour solution injectable
- Pharmaceutical form
- poudre et solvant pour solution injectable
- Route of administration
- intraveineuse;sous-cutanée
- Presentation description
- 7 (7x1) flacons en verre de 10 mg - 7 (7x1) seringues préremplies en verre de 1 ml avec 7 (7x1) adaptateurs pour flacon, 7 (7x1) aiguilles hypodermiques (30G), 14 (7x2) tampons imbibés d’alcool (Boite multidose)
- Marketing authorisation holder
- ABLYNX (BELGIQUE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 31 Jul 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64183564CIP73017275CIP133400930172759Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CAPLACIZUMABpoudre | 10 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.